UPDATE: Zevra Therapeutics Q2 Adj. EPS $0.25 Beats $0.14 Estimate, Sales $39.663M Beat $33.572M Estimate
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.14 by 78.57 percent. This is a 79.84 percent decrease over earnings of $1.24 per share from
Zevra Therapeutics made more money than experts thought it would this quarter—both in profits per share and total sales. When a company beats what people expected, it can mean the business is doing better than planned, so it's worth watching how the company performs in coming quarters.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.